LY3300054 + merestinib

**LY3300054 + merestinib** is a combination therapy of two investigational anticancer agents, studied for advanced, refractory solid tumors. LY3300054 is a monoclonal antibody that inhibits programmed cell death ligand 1 (**PD-L1**), thereby blocking immune evasion by tumor cells and activating T-cell mediated antitumor immunity. Merestinib is a small molecule, oral multikinase inhibitor, primarily targeting the hepatocyte growth factor receptor (**MET**), with additional activity against other kinases such as FGFR, DDR1, and AXL. The combination aims to provide synergistic antitumor effects by both reactivating the immune system (via PD-L1 blockade) and directly inhibiting oncogenic signaling pathways (via MET/other kinase inhibition). Eli Lilly is the developer of both agents. Clinical trials assessed safety, pharmacokinetics, and initial antitumor efficacy in patients with solid tumors, including pancreatic cancer and melanoma[1][3][5].